Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

Early pregnancy blood pressure patterns tied to hypertension risk years later
Researchers show certain blood pressure patterns during the first 20 weeks of pregnancy were more likely to develop into hypertension later in life.
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension
The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH.
Boston Scientific enters renal denervation market with acquisition worth up to $540M
Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology.
Cardiovascular societies support Medicare coverage for renal denervation
CMS is expected to release a proposed national coverage determination decision memo by July.
Momentum continues for renal denervation as CMS considers national Medicare coverage
CMS is accepting public comments on the topic for a period of 30 days. Recor Medical and Medtronic have both shared statements in support of the potential policy shift.

Ajay J. Kirtane, MD, director of the cardiac catheterization laboratories and professor of medicine at NewYork-Presbyterian/Columbia University Irving Medical Center, explains the current trial data on catheter renal denervation to treat drug-resistant hypertension at AHA 2022.

Where renal denervation stands for the treatment of drug-resistant hypertension

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic.

‘Revolutionary’ new CT scans identify the most common cause of high blood pressure

Primary aldosteronism (PA) is one the single most common causes of hypertension, but identifying patients with PA—and knowing which ones may benefit from a surgical treatment—can be quite challenging.

doctor fruits vegetables vegetarian diet

Top 15 heart-healthy diets: DASH, Mediterranean come out on top

The list represents a collaboration between more than 30 nutritionists, doctors and epidemiologists.

Former U.S. Surgeon General Jerome Adams (2017-2021) spoke at the opening session of the American Heart Association (AHA) 2022 Scientific Sessions last week and said cardiologists need to help end the COVID pandemic and tackle the even bigger epidemic of hypertension. He highlighted hypertension and called it a clear public health emergency, causing more than 670,000 U.S. deaths per year. #AHA22 #hypertension

Former surgeon general says cardiologists need to address hypertension and remaining COVID cases

Former U.S. Surgeon General Jerome Adams spoke at the AHA 2022 Scientific Sessions and asked cardiologists to help end the COVID pandemic and tackle the even bigger epidemic of hypertension.

Late-breaking cardiovascular study presentation at AHA 2022. #AHA22

VIDEO: Key takeaways from AHA 2022

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

Deepak Bhatt, MD, discusses the long-term, positive SYMPLICITY HTN-3 trial results presented at TCT 2022, and the future of renal denervation therapy to treat hypertension. #TCT

VIDEO: SYMPLICITY HTN-3 and the future of renal denervation

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension.

How the COVID-19 pandemic has impacted blood pressure management in the US

A new analysis of more than 137,000 patients found that the early months of the pandemic were associated with some concerning trends for hypertension patients.

FDA announces new recall of blood pressure medication due to potential cancer risk

Patients impacted by this recall are advised to speak with a physician about how to proceed.

Hypertension

Early pregnancy blood pressure patterns tied to hypertension risk years later

ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

Boston Scientific enters renal denervation market with acquisition worth up to $540M

Cardiovascular societies support Medicare coverage for renal denervation

Momentum continues for renal denervation as CMS considers national Medicare coverage